NR + Pterostilbene Lifts NAD+ ~40–90% in Human Trial
Can a daily capsule of nicotinamide riboside and pterostilbene raise NAD+ in older adults? In the first-in-human NRPT (Basis) trial, 120 people aged 60 to 80 took it for eight weeks. Blood NAD+ rose about 40% at the recommended dose and about 90% at double the dose, and the rise held steady through the study. No serious adverse events were reported. Here is what the numbers show, what the dose takeaways are, and what the study cannot tell you.
1,000 mg of Nicotinamide Riboside Daily Raised Blood Cell NAD+ by About 60% in Older Adults, Randomized Trial Finds
A 2018 Nature Communications crossover trial tested nicotinamide riboside at 500 mg twice daily (1,000 mg/day) for six weeks in healthy middle-aged and older adults. The supplement was well tolerated and raised NAD+ in blood immune cells by about 60% compared with placebo. Researchers also saw early signals for lower blood pressure and arterial stiffness, which they flagged as ideas for larger trials, not proven benefits. This article explains why NAD+ is thought to fall with age, what the study did, and what it cannot tell us about disease outcomes or longevity.